Key Highlights
- Third-quarter 2026 net loss was USD 1.8 million, against USD 1.5 million a year earlier.
- Cash and cash equivalents were USD 2.2 million as of September 30, 2026.
- Research and development expenses were USD 1.2 million, against USD 0.9 million.
- A supplement de novo presubmission for the Helix catheter was accepted by the FDA.
BioCardia (NASDAQ:BCDA) reported a net loss of USD 0.12 per share for the third quarter ended September 30, 2026, against an estimate of a loss of USD 0.13, with no Revenue reported against an estimate of USD 0.00. The company develops cardiovascular regenerative biotherapeutics, and its call on November 12, 2026 focused on its CardiAMP cell therapy filing in Japan and its Helix transendocardial delivery system in the United States.
Quarterly Financial Results
Chief Financial Officer David McClung said net cash used in operations during the third quarter was approximately USD 1.7 million, in line with the USD 1.7 million used in the third quarter of 2025. Year-to-date net cash used in operations was USD 5.1 million, against USD 4.9 million in the same period of 2025. The company ended the quarter with cash and cash equivalents of USD 2.2 million, which it said provides runway into 2027.
Research and development expenses were USD 1.2 million, against USD 0.9 million in the third quarter of 2025, partly due to regulatory work to advance CardiAMP in Japan and expenses to support enrollment in the CardiAMP Heart Failure III trial. Selling, general and administrative expenses were USD 0.6 million, against USD 0.55 million.
Net loss was USD 1.8 million, against USD 1.5 million a year earlier. For the nine months, net loss was USD 5.7 million, against USD 6.2 million, which the company attributed primarily to lower Research and Development expenses following completion of the CardiAMP Heart Failure trial. Nine-month research and development expenses were USD 3.4 million, against USD 3.8 million.
Regulatory Progress in Japan and the United States
Chief Executive Officer Peter Altman said the company has answered all outstanding questions to the satisfaction of Japan's Pharmaceuticals and Medical Devices Agency and is proceeding to a Shonin submission with its designated Marketing authorization holder. He said the timing is fluid and that the initial clinical indication is for approximately 20,000 patients, with approval anticipated about 12 months after the submission is completed. He also said a post-marketing study of about 200 patients is being designed with the agency and three Japanese cardiovascular societies.
In the United States, the company continues to enroll the CardiAMP Heart Failure II Trial, its confirmatory Phase III study, and is onboarding an additional 7 centers. The FDA accepted the minutes of the May 2026 meeting on Helix without changes, and the company filed a supplement de novo presubmission that the FDA accepted. Management said it plans to complete the de novo submission in the first quarter of 2027, with approval targeted for mid-2027 if the FDA meets its 150-day review goal.
Business Development
Mr. Altman said Business development is active in two areas. On the therapeutic side, he said conversations could include the company's cardiovascular pipeline, including CardiAMP for chronic myocardial ischemia and the allogeneic CardiALLO cell therapy for inflammatory heart failure. On biotherapeutic delivery, he said the company had held conversations on four separate gene therapy collaborations in the preceding 72 hours.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...